Home / Resource Library / Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma

Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma

EBMT 2021: Study examined the effectiveness of CAR T therapy axicabtagene ciloleucel for first line treatment of diffuse large b-cell lymphoma.